<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137761</url>
  </required_header>
  <id_info>
    <org_study_id>04-173</org_study_id>
    <nct_id>NCT00137761</nct_id>
  </id_info>
  <brief_title>Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study of Docetaxel in Combination With ZD 1839 (IRESSA) in Previously Treated Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what activity the combination of docetaxel and&#xD;
      Iressa have against metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iressa will be taken orally once daily without interruption. Docetaxel will be administered&#xD;
      intravenously once weekly for two out of every three weeks. Patients will also receive&#xD;
      dexamethasone the night prior, morning of, and the evening after docetaxel treatment to help&#xD;
      prevent an allergic reaction.&#xD;
&#xD;
      Every week that chemotherapy is given, blood tests and vital signs will be taken.&#xD;
&#xD;
      After the first 6 weeks of therapy a CT scan (or other radiological procedure) will be done&#xD;
      to assess the progress of the disease. If the cancer is responding to the treatment and no&#xD;
      unacceptable side effects have occured, treatment with Iressa and docetaxel will continue.&#xD;
&#xD;
      CT scans (or other radiological procedure) will be performed at week 12 and every 9 weeks&#xD;
      thereafter to monitor the progress of the disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the response rate of Iressa and docetaxel in patients with advanced pancreatic cancer following failure of gemcitabine-based therapy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety, radiologic response rate, progression-free survival and overall survival of patients treated with Iressa and docetaxel</measure>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Metastatic Pancreatic Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD 1839</intervention_name>
    <description>Taken orally once daily</description>
    <other_name>Iressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given intravenously once weekly for 2 out of 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic pancreatic carcinoma (excluding pancreatic endocrine tumors); histologic&#xD;
             confirmation of either the primary or metastatic site.&#xD;
&#xD;
          -  ECOG performance status of &lt; 1&#xD;
&#xD;
          -  &gt; 4 weeks since completion of previous chemotherapy&#xD;
&#xD;
          -  &gt; 4 weeks since participation in any investigational drug study&#xD;
&#xD;
          -  Peripheral neuropathy of grade &lt; 1&#xD;
&#xD;
          -  Patients must have failed a gemcitabine-containing regimen administered in the&#xD;
             metastatic, adjuvant, or locally advanced setting.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1,500/mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0gm/dl&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0mg/dl&#xD;
&#xD;
          -  AST and alkaline phosphatase &lt; 5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Albumin &gt; 2.5gm/dl&#xD;
&#xD;
          -  CA 19-9 &gt; 1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with taxane or with epidermal growth factor receptor (EGFR) inhibitors&#xD;
&#xD;
          -  More than one prior chemotherapy treatment&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Major surgery within 4 weeks of the start of study treatment&#xD;
&#xD;
          -  Evidence of central nervous system (CNS) metastases or carcinomatous meningitis or&#xD;
             history of uncontrolled seizures, central nervous system disorders.&#xD;
&#xD;
          -  Uncontrolled serious medical or psychiatric illness&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Other active malignancy&#xD;
&#xD;
          -  Inability to swallow tablets or evidence of a gastrointestinal malabsorption syndrome&#xD;
&#xD;
          -  Known severe hypersensitivity to Iressa&#xD;
&#xD;
          -  Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital,&#xD;
             or St. John's wort.&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to drugs formulated with polysorbate 80&#xD;
&#xD;
          -  Any evidence of clinically active interstitial lung disease&#xD;
&#xD;
          -  Ascites requiring paracentesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Kulke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>October 30, 2009</last_update_submitted>
  <last_update_submitted_qc>October 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Matthew Kulke, MD</name_title>
    <organization>Dana-Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>Pancreatic Carcinoma</keyword>
  <keyword>Iressa</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

